News

CE Mark for “CAD EYE,” to support real time detection of colonic polyps during colonoscopy utilizing AI technology.- FujiFilm

Read time: 1 mins

Published:2nd Mar 2020

FUJIFILM Europe GmbH will launch a new function known as “CAD EYE,” which was developed by FUJIFILM Corporation to support real time detection of colonic polyps during colonoscopy utilizing AI technology. CAD EYE's functionality will be available with software EW10-EC01 and the compatible expansion unit EX-1 in combination with the Fujifilm ELUXEO 7000 system. Fujifilm has already acquired CE mark for this new software EW10-EC01 and it will be launched with EX-1 in March 2020.

Condition: Endoscopy

Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Phase III BE HEARD I and II studies of Bimzelx meet primary endpoint in Hidradenitis Suppurativa.- UCB

UCB announced positive top-line results from two Phase III studies, BE HEARD I and BE HEARD II, evaluating the efficacy and safety of Bimzelx (bimekizumab) in adults with moderate to severe hidradenitis suppurativa.

1 mins

Drug news

Cosentyx shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials.- Novartis

Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile.

1 min

Drug news

Initiation of pivotal phase III clinical Trial of LBS 008 in Stargardt disease in the U.S.

Belite Bio, Inc, a San Diego based clinical stage biopharmaceutical drug development company targeting currently untreatable eye diseases, announced that it has commenced enrollment for the Phase III clinical trial of LBS 008 in patients with Stargardt Disease (STGD1), a progressively blinding disease with no approved treatment

1 min

See all news